Trials / Unknown
UnknownNCT06285136
Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult
The Second Affiliated Hospital of Kunming Medical University
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- The Second Affiliated Hospital of Kunming Medical University · Academic / Other
- Sex
- All
- Age
- 16 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study proposes to conduct a prospective, multicenter, single-arm study to explore the efficacy and safety of venetoclax in combination with high-dose decitabine (DEC3-VEN) in new diagnosed adult patients with AML, and to provide evidence for the optimal selection of clinical treatment regimens, which is planned to be conducted in 10 research centers across the country.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | DEC3-VEN | Venetoclax in combination with decitabine (+-sorafenib) Venetoclax (VEN) 100mg d1, 200mg d2, 400mg d3-14 Decitabine (DEC) 20mg/m2/q8h, d4-6 (infusion time \>2h) Sorafenib 800mg/d, d8-14 (only for FLT3/ITD mutation positive patients) |
Timeline
- Start date
- 2024-03-01
- Primary completion
- 2026-03-01
- Completion
- 2026-03-01
- First posted
- 2024-02-29
- Last updated
- 2024-02-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06285136. Inclusion in this directory is not an endorsement.